Androgen Receptor (ANDR) Antibody Blocking peptide
€293.00
In stock
SKU
AC-BP2509a
Background:
Androgen receptor (ANDR) has 3 major functional domains: the N-terminal domain, DNA-binding domain, and an androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. The gene for this protein contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of the protein. Expansion of the polyglutamine tract causes spinal bulbar muscular atrophy (Kennedy disease). Mutations are also associated with complete androgen insensitivity (CAIS). PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor; sumoylation of ANDR represses androgen receptor dependent transcription.
Other Names: Androgen receptor, Dihydrotestosterone receptor, Nuclear receptor subfamily 3 group C member 4, AR, DHTR, NR3C4
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2509a is HPHARIKLENPLD, containing a predicted sumoylation site from the central region of human ANDR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P10275
Other Accession: Q5JUN9
Gene ID: 367
Gene Name: AR
Format: The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Bio References:
Nishida, et al. J. Biol. Chem. 277 (44), 41311-41317 (2002)Sills, E.S., et al., Int. J. Mol. Med. 9(1):45-48 (2002).Chavez, B., et al., J. Hum. Genet. 46(10):560-565 (2001).Ahmed, S.F., et al., J. Clin. Endocrinol. Metab. 85(2):658-665 (2000).Marcelli, M., et al., Cancer Res. 60(4):944-949 (2000).
Androgen receptor (ANDR) has 3 major functional domains: the N-terminal domain, DNA-binding domain, and an androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. The gene for this protein contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of the protein. Expansion of the polyglutamine tract causes spinal bulbar muscular atrophy (Kennedy disease). Mutations are also associated with complete androgen insensitivity (CAIS). PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor; sumoylation of ANDR represses androgen receptor dependent transcription.
Other Names: Androgen receptor, Dihydrotestosterone receptor, Nuclear receptor subfamily 3 group C member 4, AR, DHTR, NR3C4
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2509a is HPHARIKLENPLD, containing a predicted sumoylation site from the central region of human ANDR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P10275
Other Accession: Q5JUN9
Gene ID: 367
Gene Name: AR
Format: The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Bio References:
Nishida, et al. J. Biol. Chem. 277 (44), 41311-41317 (2002)Sills, E.S., et al., Int. J. Mol. Med. 9(1):45-48 (2002).Chavez, B., et al., J. Hum. Genet. 46(10):560-565 (2001).Ahmed, S.F., et al., J. Clin. Endocrinol. Metab. 85(2):658-665 (2000).Marcelli, M., et al., Cancer Res. 60(4):944-949 (2000).
| Is Featured? | No |
|---|
Write Your Own Review